BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 22211893)

  • 21. Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin.
    Wysocki PJ; Wierusz-Wysocka B
    Expert Rev Mol Diagn; 2010 May; 10(4):509-19. PubMed ID: 20465505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AMPK activation as a strategy for reversing the endothelial lipotoxicity underlying the increased vascular risk associated with insulin resistance syndrome.
    McCarty MF
    Med Hypotheses; 2005; 64(6):1211-5. PubMed ID: 15823720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metformin and pancreatic cancer: Is there a role?
    De Souza A; Khawaja KI; Masud F; Saif MW
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):235-42. PubMed ID: 26740120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A fixed-dose combination of pioglitazone and metformin: A promising alternative in metabolic control.
    Seufert J
    Curr Med Res Opin; 2006; 22 Suppl 2():S39-48. PubMed ID: 16914074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients.
    Sciacca L; Vigneri R; Tumminia A; Frasca F; Squatrito S; Frittitta L; Vigneri P
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):808-15. PubMed ID: 23932729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs.
    McFarland MS; Cripps R
    Pharmacotherapy; 2010 Nov; 30(11):1159-78. PubMed ID: 20973689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diabetes and pancreatic cancer.
    Cui Y; Andersen DK
    Endocr Relat Cancer; 2012 Oct; 19(5):F9-F26. PubMed ID: 22843556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metformin decreases IGF1-induced cell proliferation and protein synthesis through AMP-activated protein kinase in cultured bovine granulosa cells.
    Tosca L; Ramé C; Chabrolle C; Tesseraud S; Dupont J
    Reproduction; 2010 Feb; 139(2):409-18. PubMed ID: 19906888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line.
    Lange C; Machado Weber A; Schmidt R; Schroeder C; Strowitzki T; Germeyer A
    PLoS One; 2021; 16(3):e0248103. PubMed ID: 33690729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The management of insulin resistance in polycystic ovary syndrome.
    Teede HJ; Hutchison SK; Zoungas S
    Trends Endocrinol Metab; 2007 Sep; 18(7):273-9. PubMed ID: 17698366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diabetes and cancer: a 2013 synopsis.
    Buysschaert M; Sadikot S
    Diabetes Metab Syndr; 2013; 7(4):247-50. PubMed ID: 24290094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential regulation of insulin action and tumor necrosis factor alpha system activity by metformin.
    Biarnés J; Fernández-Real JM; Fernández-Castañer M; del Mar García M; Soler J; Ricart W
    Metabolism; 2005 Feb; 54(2):235-9. PubMed ID: 15690319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metformin: an effective attenuator of risperidone-induced insulin resistance hyperglycemia and dyslipidemia in rats.
    Adeneye AA; Agbaje EO; Olagunju JA
    Indian J Exp Biol; 2011 May; 49(5):332-8. PubMed ID: 21615056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metformin: do we finally have an anti-aging drug?
    Anisimov VN
    Cell Cycle; 2013 Nov; 12(22):3483-9. PubMed ID: 24189526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Obesity related hyperinsulinaemia and hyperglycaemia and cancer development.
    Becker S; Dossus L; Kaaks R
    Arch Physiol Biochem; 2009 May; 115(2):86-96. PubMed ID: 19485704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diabetes mellitus, hyperglycaemia and cancer.
    Simon D; Balkau B
    Diabetes Metab; 2010 Jun; 36(3):182-91. PubMed ID: 20554237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP.
    Kim YD; Park KG; Lee YS; Park YY; Kim DK; Nedumaran B; Jang WG; Cho WJ; Ha J; Lee IK; Lee CH; Choi HS
    Diabetes; 2008 Feb; 57(2):306-14. PubMed ID: 17909097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice.
    Anisimov VN; Berstein LM; Egormin PA; Piskunova TS; Popovich IG; Zabezhinski MA; Kovalenko IG; Poroshina TE; Semenchenko AV; Provinciali M; Re F; Franceschi C
    Exp Gerontol; 2005; 40(8-9):685-93. PubMed ID: 16125352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A proposal for the locus of metformin's clinical action: potentiation of the activation of pyruvate kinase by fructose-1,6-diphosphate.
    McCarty MF
    Med Hypotheses; 1999 Feb; 52(2):89-93. PubMed ID: 10340287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.